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Abstract
A multimodal approach to treatment is a basic oncologic principle with proven survival ben-
efits for most cancer types. However, existing guidelines recommend single modalities for 
treating each stage of hepatocellular carcinoma (HCC). Nonetheless, multimodal approaches 
can be considered for HCC, depending on the characteristics of the disease in individual 
cases. Radiotherapy (RT), an effective local modality, is a critical element of most multimodal 
approaches. Improved RTtechnology and increased understanding of the tolerance of the 
liver to radiation have contributed to the popularity of RT for treating liver tumors in clini-
cal practice. Consequently, numerous reports have described the effects of RT on liver can-
cer, despite a lack of stringent evidence for its benefits. RT can be delivered using various 
technologies and approaches, which may be the source of some confusion. For example, 
high-dose ablative RT can be curative on its own, or high-dose ablative or conventional RT 
can complement other treatments such as radiofrequency ablation and transarterial che-
moembolization. Combinations of systemic agents and RT can also be applied. This review 
discusses the optimal selection of RT as part of a multimodal approach for HCC.
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IntroductionMultimodal treatment is a basic oncologic principle that incorporates surgery, radio-
therapy (RT), and chemotherapy [1, 2]. It has proven survival benefits for most cancer types 
[3–5]. However, a range of single modalities is generally recommended for treating each 
stage of hepatocellular carcinoma (HCC). Nevertheless, the multimodal approach may also be considered according to the disease characteristics in individual cases.
The Barcelona Clinic Liver Cancer (BCLC) staging system is most commonly used to 
stage HCC. It is endorsed by the American Association for the Study of Liver Diseases and 
the European Association for the Study of the Liver. Guidelines based on the BCLC staging 
system recommend a single modality as the standard treatment for each stage [6]. However, 
single-modality treatment frequently results in local or distant failure in the treatment of 
non-early-stage HCCs, which constitute the majority of cases [7].
The National Comprehensive Cancer Network (NCCN) guidelines recommend external-
beam RT as a locoregional therapy for potentially resectable and unresectable HCC patients 
[8]. The Korean Liver Cancer Study Group (KLCSG) guidelines, established in 2003 [9] and 
updated in 2014 [10], recommend RT depending on the stage of HCC [10]. Both the 2003 
and 2014 KLCSG guidelines support RT for the treatment of HCC because RT can exert an 
independent ablative effect and generally complements other treatments.
This article reviews the usage of RT in HCC treatment and discusses the clinical applica-
tion of RT according to the 2014 KLCSG guidelines. Ongoing clinical trials and the optimal 
selection of RT as a part of multimodal approaches to HCC treatment are also discussed.
Beneficial Effects of RT against HCC
RT was previously not indicated for HCC because of the low tolerance of the liver to 
radiation. However, since Emami et al. estimated the tolerance dose for a 5% incidence of 
radiation-induced liver disease (RILD) in 5 years (TD5/5) after one-third liver irradiation to 
be 50 Gy at 1.8–2 Gy/fraction [11], several studies have confirmed high levels of tolerance 
of focal liver irradiation. For one-third of the liver irradiated, the estimated TD5/5 value is 
reportedly >40 Gy [12, 13]. A group from the University of Michigan also proposed that the 
delivery of >100 Gy may be possible without high risk of RILD if the effective irradiated liver 
volume is <25% [14]. Furthermore, technological progress in RT from three-dimensional 
conformal RT (3D-CRT) to intensity-modulated RT (IMRT), image-guided RT, and stereotac-
tic body RT (SBRT) has enabled the delivery of high-precision RT for local HCC accompanied 
by minimal doses to the normal liver volume without inducing RILD [15–30].
RT for HCC can improve therapeutic outcomes through excellent local control, down-
staging, conversion from unresectable to resectable status, and inhibition of intrahepatic 
metastasis. Excellent local control rates produced by SBRT can lead to favorable survival 
outcomes without severe radiation-induced toxicities, including 2-year overall survival (OS) 
rates of 53–61%, response rates of 45–63%, and grade 3 hepatic toxicity incidence rates 
of 6.5–16% [15, 16, 31, 32]. Local RT combined with systemic chemotherapy can result in 
downstaging and can subsequently convert the tumor status from unresectable to resect-
able. Downstaging may allow some patients to undergo radical resection, thereby improv-
ing long-term survival [33]. Local RT for major tumors and portal vein tumor thrombosis 
(PVTT) may prevent rapid intrahepatic metastasis, an adverse prognostic factor that makes 
it difficult to determine the best treatment strategy [18]. Compared to 3D-CRT, using inten-
sity-modulated image-guided RT (IG-IMRT) as an advanced technique to apply high-dose RT 
to the partial liver in locally advanced HCC patients with good performance status and good 
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hepatic function reduces infield failure (29.2% vs. 44.3%, p=0.045) and improves survival (20 
vs. 10 months, p<0.001) [18]. These findings suggest that high-dose, high-precision RT may 
have survival benefits.
RT According to Modified UICC TNM Stage
Unlike the BCLC staging system, the Union for International Cancer Control (UICC) stag-
ing system is anatomically based, describing the disease according to the extent of the pri-
mary tumor (T), regional lymph node involvement (N), and the presence (or otherwise) of 
distant metastases (M) [34, 35]. The UICC system describes the primary tumor site based on 
whether it meets the following criteria: (1) number of tumors: solitary; (2) diameter of the 
largest tumor: no more than 2 cm; and (3) no vascular or bile duct invasion. Stage T1 is de-
fined as a primary tumor that fulfills all three criteria, T2 is a primary tumor that fulfills two 
of the three criteria, T3 is a primary tumor that fulfills one of the three criteria, and T4 is de-
fined as a primary tumor that fulfills none of the criteria. Categories N and M describe regional 
lymph node involvement and distant metastasis, respectively. The modified UICC (mUICC) 
staging system categorizes HCC with T1, N0, and M0 as stage I and HCC with T2, N0, and M0 as 
stage II. T3N0M0 HCC patients are grouped as stage III. The mUICC staging system classifies 
T4N0M0 or N1M0 with any T stage as stage IVA and distant metastatic HCC as stage IVB. The 
fifth version of the mUICC staging system was adopted as the primary staging system for HCC 
by the KLCSG and National Cancer Centre (NCC) Korea in 2003.
The 2014 KLCSG guidelines recommend RT as an alternative for HCC patients unsuit-
able for surgical resection, radiofrequency ablation (RFA), ethanol injection, or transarterial 
chemoembolization (TACE) for mUICC stage I. For a single stage II HCC tumor >2 cm without 
vascular/ductal invasion, RT is also an alternative option in patients unsuitable for surgical 
resection, RFA, TACE, or liver transplantation. For a single tumor <2 cm with vascular invasion 
in stage II HCC, RT is one of the best therapeutic options. RT is also recommended as one of the 
best therapeutic options for a single stage III HCC >2 cm with major vascular invasion [10].
SBRT for mUICC Stage I/II HCC
Curative therapies can improve survival in early-stage HCC patients. However, the risk of 
complications from local ablation increases in tumors located below the hepatic dome and 
adjacent to the main portal vein (PV). RT may be a feasible alternative for these patients, espe-
cially for those who are inoperable or refuse surgery. Local high-dose RT, including SBRT, can 
be an appropriate alternative definitive or salvage treatment [36–41] (table 1). A French pro-
spective trial evaluated the feasibility and efficacy of high-dose 3D-CRT in cirrhotic patients 
with small HCC: 66 Gy was delivered in 33 fractions, resulting in a tumor response rate of 92% 
[39]. Bae et al. also investigated the tumor response and local control rates in patients who 
underwent salvage hypofractionated RT of 50 Gy in 10 fractions. They reviewed 20 patients 
with HCC ≤5 cm and no PVTT; the complete response (CR) and in-field control rates were 
35% and 85%, respectively [40]. Andolino et al. investigated the safety and efficacy of SBRT 
in 60 patients with primary, liver-confined HCC: the 2-year local control, progression-free 
survival (PFS) rate, and OS rate were 90%, 48%, and 67%, respectively [36]. Andolino et al. 
thereby demonstrated that SBRT is a safe, effective, and noninvasive option for HCC ≤6 cm and 
that SBRT can be considered as bridging locoregional therapy to transplantation or definitive 
therapy in patients ineligible for transplantation. O’Connor et al. reported the safety and effi-
cacy of SBRT as a bridge to transplantation for HCC [42]; patients underwent orthotopic liver 
transplantation after SBRT with a median time from SBRT to liver transplantation of 113 days 
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(range: 8–794 days). The 5-year overall and disease-free survival rates were both 100%, 
whereas the pathologic CR rate was 27%. These results show that SBRT has clinical value as 
a bridging therapy to transplantation as part of a multimodal approach.
Additional RT after Incomplete Response to TACE or RT for HCC Unfit for TACE in mUICC 
Stage II/III HCC
Patients diagnosed with stage II/III HCC can benefit from TACE [43]. However, TACE has limitations, including vascular shunting, recanalization around the tumor capsule, and the 
development of multiple feeding vessels [44, 45]. Although TACE is repeatedly performed 
to overcome these limitations, it commonly leads to outgrowth of HCCs refractory to TACE. 
RT can be useful as a complementary modality. TACE followed by RT is a feasible and ef-
fective complementary treatment for patients with incomplete necrosis after TACE [46–49] (table 2). A meta-analysis demonstrated that TACE in combination with RT significantly im-
proves the 5 year-survival (odds ratio [OR]: 4.47, 95% confidence interval [CI]: 2.08–9.61, 
p=0.0001) and tumor CR (OR: 2.58, 95% CI: 1.64–4.06, p=0.0001) rates compared to TACE 
alone [50]. A recent prospective phase II multicenter study investigated the efficacy and tox-
icity of RT following an incomplete response to TACE [51]; 31 patients who still had viable 
tumors after no more than three courses of TACE were enrolled, whereas patients with main 
PV invasion were excluded. The primary endpoint was tumor response. A best objective in-
field response rate was achieved in 83.9% of patients, with 22.6% of patients achieving CR 
within 12 weeks of RT. The 2-year in-field PFS, PFS, and OS rates were 45.2%, 29.0%, and 
61.3%, respectively. These findings demonstrate that early application of 3D-CRT can be a 
practical option in multimodal approaches for patients with incomplete necrosis after TACE. 
For patients unsuitable for TACE therapy because of low vascularity or PVTT, RT could be 
also effective and feasible. Yoon et al. reported the clinical outcomes of patients after TACE 
for primary tumors who underwent RT for HCC with PVTT [52]: 3.6% and 24.3% of such 
patients achieved CR and partial response (PR), respectively. The 1- and 2-year survival rates 
were 42.5% and 22.8%, respectively. The treatment response was an independent prognos-
tic factor associated with OS (stable disease vs. CR and PR: hazard ratio [HR]: 3.06, 95% CI: 
2.38–3.94; p<0.01) and treatment response was the most powerful predictor of survival in 
multivariate analysis (median survival of 19.4 months in responders and 7 months in non-
responders, p<0.001) [52]. TACE plus RT resulted in significantly better OS than sorafenib 
only in advanced HCC (14.1 vs. 3.3 months before matching propensity scores and 8.9 vs. 3.1 
months after matching propensity scores, p<0.001) [53]. A recent study demonstrated that 
SBRT is feasible and can be effective for HCC patients who are refractory to, or unsuitable 
for, TACE, showing a CR rate of 32.8%, a 2-year in-field failure-free rate of 66.8%, a median 
survival time (MST) of 20 months, and an RILD incidence rate of 9.4% [54].
Concurrent Chemoradiation with Hepatic Arterial Infusion in mUICC Stage II/III HCC with 
Vascular Invasion
PVTT, the most detrimental feature of vascular invasion in HCC, has been a major ob-
stacle to HCC management and limits the therapeutic options. However, PVTT is sensitive 
to RT, and the response rate ranges from 25% to 61.5% [52, 55–58]. Furthermore, RT can 
boost the treatment responses of tumors and PVTT, and thus likely bestows a survival ben-
efit [33, 52, 59–62]. In one retrospective study, preoperative RT induced PVTT necrosis in 
8 patients (53.3%), and preoperative RT followed by surgery resulted in better outcomes 
than surgery alone for HCC with PVTT (5-year survival rate: 34.8% vs. 13.1%, p=0.0359) 
[61]. Better PVTT responses to RT were significantly associated with better survival [59, 60]. 
Several studies have indicated that hepatic arterial infusion concurrent chemoradiation 
(HAICCRT) may be a feasible and effective alternative for unresectable liver-confined HCC 
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with vascular invasion [33, 55, 62–64] (table 3). The MST of patients who undergo HAIC-
CRT ranges from 11.4 to13.1 months. The PVTT response to HAICCRT indicates significant 
survival improvement [62], with CR and PR rates of 14% and 48%, respectively. Moreover, 
PVTT CR is a significant prognostic factor (HR: 0.445, 95% CI: 0.205–0.968, p=0.041). The 
objective responses of both the primary tumor and PVTT are significantly associated with 
improved survival (median: 16.7 months, p=0.002). RT-induced downstaging can allow cu-
rative resection to be carried out and provide a curative opportunity for some unresectable 
liver-confined HCC patients [33]. Among 243 patients treated between 2005 and 2011, 41 
(16.9%) underwent curative resection following HAICCRT. The response rate (CR + PR) was 
65.9%, and the downstaging rate was 78%. Patients who underwent curative resection af-
ter HAICCRT exhibited significantly higher OS than those who did not (5-year OS: 49.6% 
vs. 9.8%; p<0.001). A nationwide cohort study also supports the use of HAICCRT as part 
of a multimodal approach [64]. After propensity score matching, the HAICCRT group had 
a significantly better OS (median: 11.4 months) than the non-HAICCRT group (median: 6.6 
months, p=0.02); multivariate analysis of all patients showed HAICCRT was an independent 
prognostic factor for OS (non-HAICCRT vs. HAICCRT, HR: 1.48, 95% CI: 1.11–1.97, p=0.007).
Multimodal Approaches Involving RT for Large, Unresectable HCC (≥5 cm)
Multimodal approaches involving RT can affect outcomes in patients with large, unre-
sectable HCCs. Shim et al. compared TACE followed by RT versus TACE alone or repeated 
TACE [48] (table 3). The inclusion criteria were as follows: (1) single tumors ≥5 cm in diam-
eter receiving TACE as the primary treatment, and (2) patients with PV invasion exceeding 
the segmental branch. The response to TACE alone was incomplete in 69.5% of 105 patients. 
Of the 73 patients with HCC with an incomplete response to TACE, 38 underwent RT and 35 
underwent repeated TACE alone. Comparison of RT following incomplete TACE with TACE 
alone showed that the addition of RT remedied incomplete necrosis after TACE and signifi-
cantly increased 2-year OS (TACE alone vs. TACE plus RT, 14% vs. 37%, p=0.001). The im-provement in survival was greater in patients with large tumors. Two-year survival rates 
for TACE plus RT versus TACE alone were 63% and 42%, respectively, for tumors 5–7 cm in 
diameter, 50% and 0% for tumors 8–10 cm in diameter, and 17% and 0% for tumors >10 cm 
in diameter. HAICCRT followed by hepatic arterial infusion chemotherapy (HAIC) or TACE 
and RT combination therapy also induced excellent intrahepatic control and improved sur-
vival in unresectable very large HCCs (≥10 cm) [65] (table 3). The MSTs of patients with very 
large HCCs who underwent RT and TACE combination therapy (15.3 months) and HAICCRT 
(12.8 months) were significantly higher than those of patients undergoing TACE alone (7.5 
months) or HAIC alone (8.2 months); the time to intrahepatic progression was also signifi-
cantly greater in those undergoing HAICCRT or combined RT and TACE compared with the 
other two groups. Multivariate analysis showed that multimodal approaches, including HAI-
CCRT followed by HAIC and TACE and RT combination therapy, are significant independent 
prognostic factors that positively affect OS.
Multimodal Approaches Involving RT for Multiple mUICC Stage II/III HCCs
The role of local RT is more uncertain for multiple intrahepatic HCCs. In a study of 107 
patients with multiple intrahepatic HCCs, local RT to the main tumor was beneficial if HCCs 
external to the RT field were already well controlled by another therapy. Patients with viable 
intrahepatic tumors external to the RT field showed poorer survival than those without such 
tumors, suggesting that RT is not effective in these patients [66] (table 3). The combination 
of HAICCRT to the main tumor with PVTT and TACE to other intrahepatic tumors is effective 
for advanced HCC with both PVTT and intrahepatic metastasis [67]. Median PFS and OS were 
4.5 and 9.8 months, respectively. These findings suggest that local RT administered to the 
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main tumor in a multimodal approach can provide survival benefits for patients with mul-
tiple HCCs who have well-controlled intrahepatic tumors external to the RT field. However, a 
well-designed prospective trial is required for confirmation.
Clinical Trials Investigating the Role of RT in Multimodal Approaches to HCC 
Treatment
Clinical trials have investigated the effect and feasibility of RT for HCC. Five phase 3 clini-
cal trials have been registered at ClinicalTrials.gov and are recruiting patients to evaluate 
the effect of RT in multimodal approaches to HCC treatment (table 4). Trial NCT02125396, 
titled Adjuvant Radiotherapy Comparing TACE for Curative HCC: a Randomized Controlled 
Trial, is investigating the efficacy of adjuvant RT compared to adjuvant TACE for HCC patients 
who have undergone curative surgery and have risk factors for recurrence on pathologic 
reports. Risk factors for recurrence are tumors >5 cm, multiple nodules, vascular invasion, 
the absence of tumor capsule, poorly differentiated tumor, and a narrow resection margin. 
The primary and secondary endpoints are OS and recurrence rate, respectively. Meanwhile, a 
randomized phase III trial titled A Trial on SBRT after Incomplete Transcatheter Arterial Em-
bolization (TAE) or TACE versus Exclusive TAE or TACE for Inoperable HCC (NCT02323360) 
is recruiting participants to compare the effects of SBRT or a new cycle of TACE after incom-
plete TACE for unresectable HCC. Patients must have a single nodule ≤5 cm or one to three 
nodules ≤3 cm in diameter after incomplete TACE. The primary endpoint is local control. 
Two other clinical trials are currently recruiting participants to evaluate the effect of com-
bining RT with sorafenib versus sorafenib alone for advanced HCC. The Randomized Con-
trolled Trial of Proton Beam Radiotherapy+ Sorafenib versus Sorafenib for Patients with He-
patocellular Carcinoma Exceeding San Francisco Criteria (NCT01141478) aims to determine 
whether proton beam RT plus sorafenib will produce better results than sorafenib alone for 
treating HCC patients with a tumor burden that exceeds the San Francisco criteria. The other 
trial, The Radiation Therapy Oncology Group 1112 trial titled Randomized Phase III Study of 
Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocel-
lular Carcinoma (NCT01730937), is currently recruiting participants to compare the effect 
of SBRT followed by sorafenib with sorafenib alone for primary or recurrent advanced HCC. 
The primary endpoint of these two clinical trials is OS.
Optimal RT in Multimodal Approaches to HCC Treatment
Hepatic Functional Reserve
HCC patients are required to have sufficient hepatic functional reserve before RT. Ac-
cording to the 2014 KLCSG-NCC Korea practice guidelines [10], Child–Pugh class A or B pa-
tients are eligible for SBRT and fractionated RT [68]. Yoon et al. investigated whether poor 
hepatic function can predict radiation-induced hepatotoxicity according to the pre-RT value 
of the indocyanine green retention rate 15 min after administration (ICG-R15) in patients 
with HCC treated with RT [69]. The incidences of RILD in patients with ICG-R15 levels ≥22% 
and <22% before RT were 40.7% and 3.4%, respectively (p<0.001). Consequently, patients 
with poor hepatic functional reserve may be vulnerable to radiation-induced hepatic toxicity despite receiving an appropriate RT dose.
HCC patients hoping to undergo RT must meet several conditions to sustain sufficient 
hepatic functional reserve; these conditions take into account the tumor volume, the irra-
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diated liver volume, and dose–volume parameters. According to the 2014 KLCSG-NCC Ko-
rea practice guidelines, the tumor volume must be limited to ≤70% of the total liver volume 
[14, 70]. The liver volume receiving ≥30 Gy must be constrained to ≤60% of the total liver vol-
ume on dose–volume histograms for 3D-RT planning [71]. For SBRT, the normal liver volume 
receiving a total dose of <15 Gy must be ≥700 ml or the mean normal liver dose (liver minus 
gross tumor volume) must be limited to <28 Gy in 2-Gy fractions [72, 73]. Several institutions 
have similarly applied dose–volume histogram parameter-based RT guidelines [74, 75].
Published Dose Fractionation for Each RT Technique
The dose prescribed for SBRT has been reported as total doses of 30–60 Gy/5–20 Gy per 
fraction in several studies [15, 16, 31, 36, 40–42, 76]. With 3D-CRT or IMRT, total doses of 
21–60 Gy/1.8–5 Gy per fraction have been reported [18, 47, 49, 51, 59, 64, 65, 67, 77].
Optimal RT Strategy according to Tumor Staging
Until 2014, the NCCN guidelines recommended RT with evidence level 2B for unresect-
able HCC patients who were not transplant candidates only [8]. The 2015 NCCN version 2.0 guidelines consider locoregional therapies such as ablation, arterially directed therapy, and 
RT as preferred therapies for patients with unresectable disease and medically inoperable 
patients [8]. Furthermore, RT is suggested as a preferred treatment for potentially resectable 
HCC patients who are not amenable to resection or liver transplantation; the evidence level is 2B.
On the basis of several studies and guidelines, our recommendations for RT for the treat-
ment of HCC are as follows (fig. 1). (1) For single small mUICC stage I/II HCCs without vascular 
invasion, high-dose RT such as SBRT is an alternative option in patients unsuitable for surgi-
cal resection, liver transplantation, RFA, ethanol injection, or TACE. (2) For mUICC stage II/III 
patients who exhibit an incomplete response to TACE, combination TACE and RT as salvage 
Table 4.   Clinical trials investigating the role of RT in multimodal approaches to HCC treatmentTitle NCT number Estimated  enrollment Arms Primary  endpoint Secondary endpoint
Adjuvant Radiotherapy  
Comparing TACE for  
Curative HCC (ARTC-HCC)
NCT02125396 150 Arm 1:  
adjuvant RT 
Arm 2: TACE
OS Recurrence rate
A Trial on SBRT after  
Incomplete TAE or TACE  
versus Exclusive TAE or  
TACE for Treatment of  
Inoperable HCC
NCT02323360 80 After TAE or  
TACE 
Arm 1: SBRT,  
Arm 2: TACE
Local  control OS, PFS,  toxicity
Proton Beam Radiotherapy  
Plus Sorafenib Versus  
Sorafenib for Patients with  
Hepatocellular Carcinoma  
Exceeding  
San Francisco Criteria
NCT01141478 220 Arm 1: sorafenib 
Arm 2: proton beam RT plus 
sorafenib
OS Radiological progression
Sorafenib Tosylate with or  
without Stereotactic Body  Radiation Therapy in  Treating Patients with  
Liver Cancer
NCT01730937 368 Arm 1: sorafenib 
Arm 2: SBRT  
plus sorafenib
OS TTP, PFS, G4 or 5 adverse events,  health-related 
quality of life
TTP=time to progression.
148
Yoon et al.: Optimal Selection of Radiotherapy in HCC
Liver Cancer 2016;5:139–151
DOI: 10.1159/000367762
Published online: March 17, 2016
© 2016 S. Karger AG, Basel
www.karger.com/lic
or adjuvant treatment can be considered. (3) For mUICC stage II/III/IVa HCC with vascular 
invasion or a large diameter, RT can be part of multimodal treatments such as HAICCRT and 
TACE plus RT; if satellite nodules can be included in the RT field of the major tumor, HAICCRT 
can be applied for multiple HCCs with vascular invasion. SBRT may also be considered for 
HCC with vascular invasion. (4) For multiple HCCs in mUICC stage III/IVa patients, a combi-
nation of RT for the main tumor and TACE for intrahepatic metastasis can be considered as an alternative treatment.
Summary and Future Directions
Thanks to recent advances in RT techniques and several studies supporting its clinical 
applicability, RT has become a feasible therapeutic option for HCC. Multimodal approaches 
involving RT can be considered for HCC ranging from very early to advanced stages. High-
dose ablative RT delivered in a few fractions can be independently curative. A high ablative 
dose or conventional RT can complement incomplete results of other treatments such as 
RFA and TACE. Moreover, a combination of systemic agents and RT can be applied. However, 
additional randomized controlled trials are required to corroborate the role of multimodal 
approaches involving RT for the treatment of HCC.
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